(IN BRIEF) Researchers at the University of Bristol have developed a promising new gene therapy that could help prevent diabetic kidney disease in people with type 1 diabetes. The treatment uses a harmless virus to deliver the VEGF-C protein directly … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged albuminuria, Aldara Martin Alonso, American Diabetes Association, biomedical research, Bristol Medical School, Chronic kidney disease, diabetes complications, Diabetes UK, Diabetes UK and University of Bristol Study Finds Gene Therapy Could Halt Kidney Disease Progression, diabetic kidney disease, Faye Riley, gene therapy, glomerulus, kidney health, Molecular Therapy, Rebecca Foster, Translational Health Sciences, type 1 diabetes, University of Bristol, University of Bristol Researchers Pioneer New Gene-Based Treatment for Diabetic Kidney Damage, University of Bristol Unveils Gene Therapy Breakthrough to Prevent Kidney Disease in Type 1 Diabetes, VEGF-C
CareLink® Portfolio Updates, IBM Watson Partnership Progress and New Strategic Alliances Delivering Intelligent Data and Actionable Information at ADA 2016 DUBLIN and NEW ORLEANS, 10-Jun-2016 — /EuropaWire/ — Delivering on its vision to transform care for the millions currently living with … Read the full press release
Posted in Healthcare, Ireland, Pharma & Biotech, Technology
Tagged ADA, American Diabetes Association, Annette Brüls, diabetes management, Medtronic
2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science
Tagged 73rd Scientific Sessions®, American Diabetes Association, Boehringer Ingelheim, Diabetes, dipeptidyl peptidase-4, DPP-4, Dr. Odd Erik Johansen, Eli Lilly, Germany, Indianapolis, Ingelheim, Linagliptin, T2D, type 2 diabetes, US
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?